Episode 2: Venous Thromboembolism in a Patient with NVAF

Agnelli G, Becattini C, Meyer G, et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Eng J Med. 2020;382:1599-1607.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med . 2013;369:799-808.
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117: 219-230.
Belen E, Canbolat IP, Bayyigit A, et al. A new gap in the novel anticoagulants’ era: undertreatment. Blood Coagul Fibrinolysis. 2015;26:793-797.
Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost. 2017;43:849-863.
Borne RT, O'Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17:236.
Carrier M, Blais N, Crowther M, et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol. 2018;25:329-337.
Christiansen CB, Gerds TA, Olesen JB, et al. Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace. 2016;18:1689-1697.
Dillinger J, Aleil B, Cheggour S, et al. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: why we should not underdose our patients. Arch Cardiovasc Dis. 2018;111:85-94.
Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromsø study. J Thromb Haemost. 2015; 13:10-16.
Farge D, Frere C, Connors JM, et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566-e581.
Gorst-Rasmussen A, Skjøth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13:495-504.
Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
Jackson LR 2nd, Kim S, Blanco R, et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020;226:85-93.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104-132.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352.
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520.
Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16:1891-1894.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609-1678.
Konstantinides SV, Meyer G, Becattini C, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543-603.
Obi M, Packer CD. Submassive pulmonary embolism: a re-evaluation of hemodynamic instability monitoring. Cureus. 2019;11:e4644.
Onuk T, Karataş MB, İpek G, et al. Higher CHA2DS2-VASc score is associated with increased mortality in acute pulmonary embolism. Clin Appl Thromb Hemost. 2017;23:631-637.
Overvad TF, Skjøth F, Albertsen IE, et al. Should we reintroduce previous venous thromboembolism into decision-making for anticoagulation in atrial fibrillation? Insights from a nationwide cohort. Am J Med. 2020. doi:10.1016/j.amjmed.2020.05.042 [Epub ahead of print]
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624.
Ruiz Ortiz M, Muñiz J, Raña Míguez P, et al; FANTASIIA study investigators. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20:1577-1583.
Shore S, Carey EP, Turkhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167:810-817.
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Gregory Y.H. Lip, MD

Price-Evans Chair of Cardiovascular Medicine
University of Liverpool
Director, Liverpool Centre for Cardiovascular Science
Liverpool Heart & Chest Hospital
Liverpool, United Kingdom

Disclosures

Disclosure: Gregory Y.H. Lip, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi-Sankyo; Janssen; Medtronic; Novartis; Pfizer; Verseon
Served as a speaker or a member of a speakers bureau for: Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi-Sankyo; Janssen; Medtronic; Novartis; Pfizer; Verseon

Giancarlo Agnelli, MD

Professor, Internal Medicine
University of Perugia
Director, Internal, Vascular, and Emergency Medicine - Stroke Unit
Ospedale S. Maria della Misericordia
Perugia, Italy

Disclosures

Disclosure: Giancarlo Agnelli, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol Myers Squibb; Daiichi Sankyo; Pfizer
Served as a speaker or a member of a speakers bureau for: Bristol Myers Squibb; Bayer; Pfizer

Editors

Lih-Fan Chang, MD, MPH

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Lih-Fan Chang, MD, MPH, has disclosed no relevant financial relationships.

Philippa M. Berman, BA (Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA (Hons), MBBS, has disclosed no relevant financial relationships.

Kevan H. Chambers, CBiol, MRSB

Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Kevan H. Chambers, CBiol, MRSB, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott

processing....

Legendas em português

« Return to: Episode 2: Venous Thromboembolism in a Patient with NVAF

Activity Transcript

References

Faculty and Disclosures

Faculty

Gregory Y.H. Lip, MD

Giancarlo Agnelli, MD

Editors

Lih-Fan Chang, MD, MPH

Philippa M. Berman, BA (Hons), MBBS

Kevan H. Chambers, CBiol, MRSB

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Episode 2: Venous Thromboembolism in a Patient with NVAF

Legendas em português